Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | IL2 | P60568 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.32 |
| ▸ | TYMS | P04818 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | EDNRA | P25101 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6027097 | 0.94 | MRGPRX4 (0.36) | MEN1KMT2AMAPTSMN1; SMN2RAB9A | |
| SCHEMBL6026821 | 0.91 | MAPT (0.32) | MEN1KMT2AMAPTCYP1A2ALDH1A1 | |
| SCHEMBL6026677 | 0.86 | CSNK2A2 (0.32) | MAPTRAB9ALMNA | |
| SCHEMBL4876565 | 0.85 | EDNRA (0.37) | MEN1KMT2AMAPTSMN1; SMN2RAB9A | |
| SCHEMBL6027241 | 0.82 | GLS (0.33) | MEN1KMT2APOLB | |
| SCHEMBL6467695 | 0.82 | CHRM4 (0.32) | MEN1KMT2A | |
| SCHEMBL6029059 | 0.81 | FFAR1 (0.34) | — | |
| SCHEMBL6812848 | 0.75 | EDNRA (0.47) | MEN1KMT2AMAPTTP53LMNA | |
| SCHEMBL6812788 | 0.75 | EDNRA (0.51) | MEN1KMT2AMAPTSMN1; SMN2RAB9A | |
| SCHEMBL6817003 | 0.75 | EDNRA (0.41) | MEN1KMT2AMAPTSMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1664037-A1 | HALO SUBSTITUTED BENZO [B] THIOPHENES WITH PI3K INHIBITORY ACTIVITY AS THERAPEUTIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050096350-A1 | Halo substituted benzo[b]thiophenes as therapeutic agents | CONNOLLY MICHAEL K (US) | 2005-05-05 | — | — | US | disclosed |
| WO-2005023800-A1 | HALO SUBSTITUTED BENZO`B! THIOPHENES WITH PI3K INHIBITORY ACTIVITY AS THERAPEUTIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096350-A1 | Halo substituted benzo[b]thiophenes as therapeutic agents | HCLS1, BRI3BP, BRPF1 | MEN1 3391/4885KMT2A 3608/4885MAPT 4277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.